INTERVENTIONALPROTOCOL REGISTERED2022-000271-39
Single-arm, open-label dose titration phase 2 clinical trial of (+)-α-DHTBZ for the treatment of tardive dyskinesia (TD)
Tardive dyskinesia
Locally preserved from EU Clinical Trials Register (EudraCT)Open EU Clinical Trials Register (EudraCT)↗last source update not reported
What this record can show
Protocol only - no registry results posted
This locally preserved record separates the registered protocol from source-reported registry results. Neither is a treatment recommendation.
Registry facts
Study at a glance
- Phase
- Not reported
- Enrollment
- Not reported
- Start date
- 2022-09-02
- Sponsor
- Adeptio Pharmaceuticals Ltd
- Design
- Not reported
- Locations
- 0
- Results record
- Not present in registry snapshot
Tardive dyskinesiaTardive dyskinesia
Linked local records
Related local records
Local links use governed condition terms or exact source-reported intervention names. They are navigation candidates, not efficacy claims.
Conditions
No published condition report matched.
Cannabinoids and active compounds
No governed compound link was found.
Medicines
No exact medicine-name link was found.
Interventions
What was registered
No structured intervention was reported.
Eligibility
Population and criteria
- Sex
- Not reported
- Minimum age
- Not reported
- Maximum age
- Not reported
- Healthy volunteers
- Not reported
No structured eligibility criteria were reported.
Publications
Locally readable linked articles
No exact PMID-linked public article is currently readable locally.
Snapshot provenance
- Snapshot
- f82c8a9e-9a54-4f01-887c-7268517e1443
- Retrieved
- 25/09/2026, 08:45:44
- SHA-256
- 0b96d33010b552c063c3f4047f824f73cb8d509df090011b2bebc93a65efeb56